Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Fig. 3

ONC201 does not impact VEGF expression in xenografts or HUVEC sprouting. a VEGF-A expression as detected by immunohistochemistry in HT29 and HCT116 CRC xenografts. b HUVEC representative images of sprouting from HUVECs grown on Matrigel. c Quantitation of HUVEC sprouting and branching after 12 h of drug treatment. In vivo: n = 5 ONC201 treatment dose was 50 mg/kg weekly. HUVECS N = 4, ONC201 treatment dose 5 μM, bevacizumab dose 5 mg/ml

Back to article page